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Abstract
Background: Focal therapy as a treatment option for localized prostate cancer (PCa) is
an increasingly popular and rapidly evolving field.
Objective: To gather expert opinion on patient selection, interventions, and meaningful
outcome measures for focal therapy in clinical practice and trial design.
Design, setting, and participants: Fifteen experts in focal therapy followed a modiﬁed
two-stage RAND/University of California, Los Angeles (UCLA) Appropriateness Method-
ology process. All participants independently scored 246 statements prior to rescoring at
a face-to-face meeting. The meeting occurred in June 2013 at the Royal Society of
Medicine, London, supported by the Wellcome Trust and the UK Department of Health.
Outcome measurements and statistical analysis: Agreement, disagreement, or uncer-
tainty were calculated as the median panel score. Consensus was derived from the
interpercentile range adjusted for symmetry level.
Results and limitations: Of 246 statements, 154 (63%) reached consensus. Items of
agreement included the following: patients with intermediate risk and patients
with unifocal and multifocal PCa are eligible for focal treatment; magnetic resonance
imaging–targeted or template-mapping biopsy should be used to plan treatment;
planned treatment margins should be 5 mm from the known tumor; prostate volume
or age should not be a primary determinant of eligibility; foci of indolent cancer can be
left untreated when treating the dominant index lesion; histologic outcomes should be
deﬁned by targeted biopsy at 1 yr; residual disease in the treated area of 3 mm of
Gleason 3 + 3 did not need further treatment; and focal retreatment rates of 20%
clishould be considered* Corresponding author. Di
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a failure of focal therapy. All statements are expert opinion and therefore constitute level
5 evidence and may not reﬂect wider clinical consensus.
Conclusions: The landscape of PCa treatment is rapidly evolving with new treatment
technologies. This consensus meeting provides guidance to clinicians on current expert
thinking in the ﬁeld of focal therapy.
Patient summary: In this report we present expert opinion on patient selection, interven-
tions, andmeaningful outcomes for clinicians working in focal therapy for prostate cancer.
# 2014 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is anopenaccessarticleunder theCCBY license (http://creativecommons.
org/licenses/by/3.0/).
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Focal therapy is gaining interest as a potential treatment for
localized prostate cancer (PCa) [1]. In this rapidly evolving
field, there is a need for robust trial designs to evaluate tissue-
preserving strategies so that clinically meaningful outcomes
can be presented to physicians and their patients. However,
there has beenmuch debate with respect to the ideal patient
group, the type of intervention, and acceptable outcomes [2].
Researchers have been involved in a phased evaluation of
focal therapy over the last 5 yr, culminating in a number of
published studies summarized in a recent systematic review
[1]. One of the next phases will involve greater targeting
precision through the possible incorporation of accurate
preoperative imaging—such as multiparametric magnetic
resonance imaging (mp-MRI) to define the desired bound-
aries of ablation—at the time of the operative intervention.
An international consensus meeting of experts was
convened to provide guidance on patient eligibility, inter-
ventions, and meaningful outcome measures for focal
therapy in clinical practice and to assist in the development
of a new focal therapy trial thatwill incorporate image fusion
in the delivery of the ablative process. Anumberof consensus
groups and panels reporting on focal therapy have used
informal or formal consensus methodology [3–5]. Our
current reportused the formalRAND/UniversityofCalifornia,
Los Angeles (UCLA) Appropriateness Methodology as a two-
stage consensus process.
2. Methods
The consensus panel consisted of 15 voting members, 1 independent
chairperson with expertise in consensus methodology (J.vdM.), and
4 nonvoting observers (I.A.D., L.S., N.M., and S.W.). Members were
selected for their expertise in focal therapy and clinical trials. Their
background and experience are outlined in Table 1. The meeting was
supported by a grant from theWellcome Trust and the UKDepartment of
Health to fund the evaluation of an MRI/ultrasound fusion device for
targeted biopsy and focal therapy. Available funding limited the total
number of participants.
The consensus process used the RAND/UCLA Appropriateness
Methodology format [6]. The 237 items on which to derive consensus
were formulated in two initial small-group rounds comprising I.A.D.,
C.M.M., J.vdM., S.W., A.M., and H.U.A., informed by current literature.
Prior to a face-to-face meeting, all participants were asked to
independently score these statements on a scale ranging from 1
(strongly disagree) to 9 (strongly agree).
At the face-to-face meeting, the premeeting scores were displayed
graphically (Fig. 1). After discussion, each panel member independentlyrescored all questions. Rewording and addition of statements were
allowed if the original text was considered by the group to be ambiguous
or not fully comprehensive.
After the meeting, agreement levels (disagree, uncertain, agree)
for each statement were calculated as the median panel score. A
median of 1–3 indicated disagreement with the statement; 4–6,
uncertainty; and 7–9, agreement. The level of consensus (interpanel
score variation) for each statement was calculated by the inter-
percentile range adjusted for symmetry (IPRAS) method [6]. An IPRAS
score >0 indicates consensus among the group, with higher scores
indicating a stronger consensus level. Only statements reaching
agreement or disagreement can be included in these recommenda-
tions.
The results presented in this paper are expert opinion and therefore
constitute level 5 evidence.
3. Results
All participants returned questionnaires prior to the
meeting, and all attended the full day. From the 237 original
statements, 17 additional statements were added, 46 were
reworded, and 8were removed during the panel discussion.
The removed questions were considered to be unnecessary
or outside the scope of this meeting.
As a result, 246 final statements were rescored at the
face-to-face meeting. Consensus was reached for 154 state-
ments (63%), indicating agreement for 85 and disagreement
for 69. The full consensus document with final statements,
agreement level, and IPRAS levels is included in Supple-
mentary Table 1.
3.1. Definition of focal therapy
Various minimally invasive tissue ablation strategies exist
for the treatment of localized PCa [1]. In clinical trials,
ablation strategies have included hemi-ablation, so-called
hockey-stick ablation (extended hemi-ablation), and quad-
rant ablation [2]. The panel agreed that focal therapy should
be defined as ablation of the dominant or index lesion only.
There was agreement that quadrant ablation is a possible
focal therapy strategy, but with a lower level of consensus
than lesion-only ablation.
Given that the ablative pattern of brachytherapy or
cryotherapy differs from that of electroporation and high-
intensity focused ultrasound, it was agreed that the
morphology of the disease should guide the selection of
the energy source to be used. If only one source of ablation is
available, there was agreement that this situation would
limit the type of focal therapy that could be delivered.
Table 1 – Consensus panel and focal therapy experience
Panel member Specialty Center Most focal therapy
experience
Other focal therapy
experience
Hashim U. Ahmed Urology UCLH, UK HIFU Cryotherapy
PDT
Electroporation
Brachytherapy
Roberto Alonzi Oncology Royal Marsden Hospital, UK Brachytherapy –
Eric Barret Urology L’Institut Mutualiste
Montsouris, France
Cryotherapy HIFU
PDT
Brachytherapy
Viktor Berge Urology Oslo University Hospital, Norway HIFU –
Simon Bott Urology Frimley Park Hospital, UK HIFU Cryotherapy
PDT
Brachytherapy
David Bottomley Oncology Leeds Teaching Hospitals, UK Brachytherapy –
Scott Eggener Urology University of Chicago Medical Centre, USA Laser photothermal –
Behfar Ehdaie Urology Memorial Sloan
Kettering Cancer
Center, USA
Cryotherapy Electroporation
PDT
HIFU
Brachytherapy
Mark Emberton Urology UCLH, UK HIFU Electroporation
PDT
Cryotherapy
Richard Hindley Urology Hampshire
Hospitals, UK
HIFU PDT
Cryotherapy
Electroporation
Tom Leslie Urology Oxford University
Hospitals, UK
HIFU PDT
Brachytherapy
Caroline M. Moore Urology UCLH, UK HIFU PDT
Brachytherapy
Peter Pinto Urology NIH, USA Laser photothermal HIFU
Cryotherapy
Brachytherapy
Thomas J. Polascik Urology Duke University Medical Centre, USA Cryotherapy Electroporation
Arnauld Villers Urology CHRU Lille, France HIFU PDT
HIFU = high-intensity focused ultrasound; NIH = National Institutes of Health; PDT = photodynamic therapy; UCLH = University College London Hospital.
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3.2.1. Risk
There was agreement, with a high level of consensus, that
based on current National Comprehensive Cancer Network
classifications [7], focal therapy should be recommended
for intermediate-risk patients. There was also agreement,
with a lower level of consensus, for treating men with low-
risk disease.
The shift in the attitude of the group over time from
providing focal treatment to low-risk patients to now
treating intermediate-risk patients was discussed. The shift
was thought to be in part because of growing confidence in
the technique and promising medium-term follow-up
results [8,9]. The group recognized concerns about overdiag-
nosis and overtreatment [10–12] and agreed that providing
focal therapy to men with well-characterized low-risk
disease would represent overtreatment and that these
men may be best served with active surveillance.
3.2.2. Prostate volume
Acknowledging that some energy sources have limitations
in their ability to treat some anatomic regions (eg, high-
intensity focused ultrasound is limited to treating anterior
lesions in small prostates only) while others do not, it wasagreed that prostate volume should not be a primary
determinant of eligibility for focal therapy.
3.2.3. Age and life expectancy
It was agreed that age should not be a primary determinant
of focal therapy, although the panel was uncertain about
whether focal treatment should be recommended for
patients <40 yr or >80 yr.
The panel was also asked to evaluate criteria other
than age when selecting patients eligible for focal therapy.
The panel agreed that patients with a World Health
Organization performance status of 0 or 1 [13] should be
recommended for focal treatment and that patients with a
performance status of 3 or 4 should not be recommended.
There was uncertainty about treating patients with a
performance status of 2.
The group agreed that focal therapy was best suited to
patients with a life expectancy of >10 yr and that this
therapy should not be applied to patients with a life
expectancy of 5 yr.
3.2.4. Preintervention diagnostics
The panel agreed that a confirmatory tissue diagnosis of
cancer should be available prior to performing focal
therapy. There was a lack of agreement for providing focal
[(Fig._1)TD$FIG]
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Fig. 1 – Examples of graphic results displayed to the panel. (a) Agree:
median score: 8; interpercentile range adjusted for symmetry (IPRAS):
6.65. (b) Disagree: median score: 2; IPRAS: 6.65. (c) Uncertain: median
score: 5; IPRAS: 1.65.
E U RO P E AN URO LOG Y 6 7 ( 2 0 1 5 ) 7 7 1 – 7 7 7774treatment without a biopsy, given that the true positive
predictive value of mp-MRI is yet to be fully quantified.
It was agreed that focal therapy can be performed in
patients who have undergone an MRI-targeted prostate
biopsy and in patients who have had a standard transrectal
ultrasound (TRUS) biopsy in which the positive cores reflect,
and are concordantwith, a high-qualitymp-MRI reported by
an expert radiologist. When using an MRI-targeted strategy,
the Standards of Reporting for MRI-targeted Biopsy Studies
guidelines [14] should be followed.
3.2.5. Disease visualization
For patients who have not had anmp-MRI because of lack of
availability or physician preference, it was agreed that onlya full transperineal template–mapping biopsy was suffi-
cient to perform focal therapy [15]. The panel did not agree
that the delivery of focal therapy can be based on only the
information from a standard or extended TRUS biopsy
without further imaging or template-mapping biopsies.
3.2.6. Previous treatment
The panel agreed that focal therapy can be applied in
patients who have already undergone one focal therapy and
in patients who have had previous whole-gland treatment.
In addition, focal therapy does not need to be limited to
patients with a primary diagnosis of PCa and can be used
in the setting of radiorecurrent disease [16] when the
recurrent disease can be accurately localized.
3.3. Intervention
3.3.1. Setting
The panel agreed that ideally, focal therapy should be
delivered as a day case procedure, and it can be delivered in
an office-based setting if the necessary equipment is in place.
3.3.2. Multifocality
Specifically addressing the question of multifocal cancer,
there was agreement that therapy should be targeted to the
index lesion. There was no agreement about whether focal
therapy should be targeted to all lesions. However, the
panel agreed that multifocal cancer should not preclude
focal therapy.
3.3.3. Untreated disease
PCa is predominantlymultifocal in the vastmajority ofmen.
The multifocal nature of PCa will mean that when using a
focal therapy strategy to treat the primary PCa, some
disease will be left untreated. As a result, the concept of
index lesion ablation or ablation of one large, high-grade
lesion has been proposed as a manner by which most men
might undergo focal therapy [17]. At the heart of what
threshold of disease clinicians are willing to leave untreated
is the definition of what constitutes clinically significant
disease.
The panel agreed that it was acceptable not to treat
lesions of Gleason grade 3 + 3 up to a maximum cancer core
length of 5 mm, although it has to be noted that the level of
consensus was higher for not treating lesions with a smaller
maximum cancer core length of 3 mm.
The panel agreed that it is not acceptable to leave
untreated lesions with Gleason grade 3 + 4 with a maxi-
mum cancer core length of 5 mm or any 4 + 3 disease of any
length. However, the panel did not reach consensus on
whether lesions with Gleason grade 3 + 4 with a maximum
cancer core length of 3 mm could be left untreated.
3.3.4. Tumor volume
The panel did not agree on a maximum tumor volume
beyond which focal therapy is deemed not suitable. Other
factors needed to be considered, including the size of the
prostate, the grade of the lesion, and the boundaries and
morphologic characteristics of the lesion.
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The panel agreed that 3 mm was an acceptable targeting
error for software delivery of focal therapy to the center of
the lesion. When performing focal therapy, an optimal
circumferential margin for treatment was deemed to be
5 mm around a lesion that was seen on imaging. This is
concordant with evidence that a targeting error in the order
of 2–3 mm will achieve a positive hit rate of 90–95% of a
0.5-ml tumor and that MRI can underestimate tumor
volume [18,19].
3.3.6. Mode of treatment
In an attempt to define which treatment modality was
preferred, multiple clinical scenarios were presented to the
panel members. No clear preference emerged, with the
discussion surrounding the idea that there is not enough
evidence to support one treatment modality over another,
and the best modality is the one that is available to the
clinician and that the clinician has experience delivering.
3.4. Outcome
3.4.1. Residual cancer
When using focal therapy to treat localized PCa, there
is potential for cancer to remain within the intended
treatment zone. The panel agreed that cancer in the
treatment zone of Gleason grade 3 + 3 with a cancer core
length 3 mm is clinically acceptable, but only if there is a
decrease from the original cancer burden. In other words,
the original cancer lesion should be of a higher grade or
higher volume than the cancer that remains in the
treatment field. Remaining lesions of Gleason grade
3 + 4 or 4 + 3 are never clinically acceptable, regardless of
cancer core length.
3.4.2. Post treatment biopsy
Itwasagreed that theoptimal time for thefirstprostatebiopsy
after focal treatment is at 1 yr. A rising prostate-specific
antigen level or suspicious areas on mp-MRI should also
trigger biopsy. Patients who have had brachytherapy may
need to wait 2 yr. The panel agreed that the biopsy should be
performed in a targeted manner, as otherwise, previously
untreated tissue could easily be inadvertently sampled.
The panel remained uncertain about whether posttreatment
biopsy should also routinely sample the untreated gland.
3.4.3. Retreatment
The panel agreed that retreatment rates of 20% with focal
therapy were clinically acceptable. There was agreement
that any subsequent whole-gland therapy reflects a failure
of focal therapy. A retreatment rate of 10% with whole-
gland therapy was considered to be clinically acceptable.
4. Discussion
4.1. Summary of findings
The results of our consensus exercise following the RAND/
UCLA Appropriateness Methodology provide guidance toclinicians who deliver focal therapy to patients with
localized PCa. The results are also helpful to clinical
researchers when planning studies evaluating the effec-
tiveness of focal treatment compared with other treatment
options.
4.2. Clinical and research implications
Our consensus panel agreed on a number of key points,
which all represent a significant shift in the thinking about
the potential role of focal treatment for patients with
localized PCa. A first example is that the panel recom-
mended focal therapy for men with intermediate-risk PCa.
Also, the panel expressed the view that any energy
modality could be used, provided that the capability of
the ablative modality and the characteristics of the disease
were taken into account when planning the treatment.
Finally, it was agreed that focal treatment could be used for
multifocal disease, secondary lesions 5 mm of Gleason
3 + 3 could be left untreated, and a reduction of grade or
burden of disease within the treated area reflects treatment
success. When selecting candidates for focal therapy, it is
important that they be properly characterized. Reports of
Gleason pattern 6metastasizing exist [20] but have occurred
in high-risk individuals who have undergone systemic
therapy and would not be selected for focal treatment.
A number of uncertainties were identified and should be
the topic of future research. The research questions include
whether one therapeutic modality is better than another in
terms of the ratio of side effects to cancer control, whether
low-volume Gleason pattern 4 could be left untreated, and
whether focal therapy compromises the application of a
subsequent radical therapy in those men who might require
it.
Whether longer-term comparative randomized studies
can be delivered to answer these questions is an open
question [21]. There remains significant skepticism on
whether such a study is feasible in both ability to recruit
and randomize and in terms of the size that would be
required to demonstrate noninferiority of focal therapy
compared with radical therapy, especially when survival is
considered.
4.3. Limitations
Expert groupmeetings can be prone to significant bias since
by their nature, they are composed of people who might
have a vested interest in the field as a whole or in particular
aspects of it. The presence of an independent chair, who
had no personal interest in the results of the consensus
exercise and who ensured that all panel members had the
opportunity to contribute to the discussions and that no
member dominated the discussions, reduced this bias. It is
also important to note that the scoringmethod—also during
the face-to-face meeting—was anonymous. We also ac-
knowledge that there was a lack of expertise in imaging and
pathology. Although this situation was decided a priori
because the questions were about delivery of focal therapy,
it may have affected our findings.
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PCa treatment is evolving with the emergence of new
ablative technologies and techniques. Guidance formulat-
ed using consensus methodology assists clinicians deliv-
ering focal therapy and helps inform future clinical trials
and research programs. In this paper we have identified
criteria for those men who may be suitable for focal
therapy and disease states that could be treated, and we
have outlined therapy-planning strategies and outcomes
that might be legitimate and acceptable for clinical
adoption if successfully met in prospective cohorts and
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